News | June 14, 2011

Positron Proposes to Build High-Energy Commercial Cyclotron in U.S.

June 14, 2011 – Positron, a molecular imaging company specializing in the field of nuclear cardiology, is relocating its corporate headquarters, research and development and product manufacturing facilities to Noblesville, Ind. Positron also plans to develop a high-energy 70 MeV cyclotron project and radiopharmaceutical manufacturing facility, also to be located in Noblesville.

Positron is proposing to make a capital investment of approximately $55 million for this project in conjunction with significant economic development incentives from the city of Noblesville and the state of Indiana, as well as various other project financing opportunities.

This cyclotron, once completed, will be the highest energy commercial cyclotron for isotope production within the United States and will advance Positron’s objectives for the production of medical isotopes and radiopharmaceuticals used in cardiac positron emission tomography (PET) imaging, diagnostic and therapeutic medical radiopharmaceuticals.

Positron’s development plans are expected to create more than 80 jobs in Noblesville over the next three to five years, a majority of which would be highly-skilled, professional positions. In addition, the city is expected to realize further economic benefits through complementary businesses locating in Noblesville in order to be in close proximity to this unique facility. The company believes Noblesville to be the ideal choice for expansion plans based on its growing economy, strategic location and the city’s commitment to promoting a thriving healthcare and technology environment.

Positron, the city of Noblesville and the state of Indiana are working to finalize a definitive agreement regarding the proposed incentive package for this project.

For more information: www.positron.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init